Genix Acquires 30 Ophthalmic Dossiers In Canada
Expects To Begin Commercialization From 2022
Executive Summary
Canadian firm Genix has acquired 30 ophthalmic generic dossiers from Canagen. Genix expects to begin commercialization from 2022.
You may also be interested in...
Deal Watch: Genentech Sees Bicycle As Route To Novel Targeted Cancer Immunotherapies
Genentech pays $30m up front in a collaboration with Bicycle in a deal that could bring the UK biotech roughly $1.7bn in total. Also, deals involving Nimble, Seattle Genetics, Five Prime, Fresenius, Vifor, Yuhan, Imnewrun, Paratek, Almirall, MBD, AzothBio, Norgine, Faes, Aspen Pharmacare, Swixx.
Shortlist Revealed Ahead Of October Awards
Ahead of the Global Generics & Biosimilars Awards, which are this year being held on Wednesday 25 October at the Hotel Porta Fira in Barcelona, we reveal our final shortlist of entrants across all 14 categories.
Teva Looks To Novartis To Replace Departing Dethlefs
Teva’s commercial interests in North America will soon be under new leadership after the firm announced that Sven Dethlefs would leave the company in mid-November. The firm has looked to the branded sector for his replacement.